This activity is supported by an independent education grant from BioNTech-BMS Alliance. This online education program has been designed for healthcare professionals globally.
Target Audience
This activity is intended for medical oncologists, pulmonologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals who care for patients with lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Faculty
Edward Garon, MD is Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA and Associate Professor at UCLA. A leading thoracic oncologist, his clinical and research interests focus on lung cancer, biomarker development, and clinical trial innovation. Dr. Garon has led numerous national and international phase I–III clinical trials, including studies that contributed to the approval of multiple cancer therapies and a companion diagnostic.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Prof. Edward Garon faculty for this educational activity, has the following relevant financial relationships: Consultant and/or Advisor for Abbvie; AstraZeneca; Arrivent; Bayer; Bicycle; Black Diamond Therapeutics; BridgeBio; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi-Sankyo; GSK; Gilead; Hexagon; I-Mab; IO Biotech; iTeos; Merck; Nuvalent; Oxford Bio; Pfizer; Regeneron; Samsung; Sanofi; Servier; Strata; Synthekine, Transcode; Verastem. Grant/Research Support (inst) from ABL-Bio; Arrivent; AstraZeneca; Bayer; BridgeBio; Bristol Myers Squibb; Daiichi Sanko; Eli Lilly; Genentech; Gilead; Iovance Biotherapeutics; Merck; Novartis; Prelude; Regeneron; Synthekine; TILT Biotherapeutics. ntellectual Property for Motif Neoepitopes for Cancer Immunotherapy
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008073-9999-26-321-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until July 14th 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This continuing education activity is active starting October 1st 2026, and will expire on July 14th 2027.
Estimated time to complete this activity: 15 Minutes
Social Media Learning Series: CME Material and Disclosures
This activity is supported by an independent education grant from BioNTech-BMS Alliance. This online education program has been designed for healthcare professionals globally.
Target Audience
This activity is intended for medical oncologists, pulmonologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals who care for patients with lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Faculty
Edward Garon, MD is Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA and Associate Professor at UCLA. A leading thoracic oncologist, his clinical and research interests focus on lung cancer, biomarker development, and clinical trial innovation. Dr. Garon has led numerous national and international phase I–III clinical trials, including studies that contributed to the approval of multiple cancer therapies and a companion diagnostic.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Prof. Edward Garon faculty for this educational activity, has the following relevant financial relationships: Consultant and/or Advisor for Abbvie; AstraZeneca; Arrivent; Bayer; Bicycle; Black Diamond Therapeutics; BridgeBio; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi-Sankyo; GSK; Gilead; Hexagon; I-Mab; IO Biotech; iTeos; Merck; Nuvalent; Oxford Bio; Pfizer; Regeneron; Samsung; Sanofi; Servier; Strata; Synthekine, Transcode; Verastem. Grant/Research Support (inst) from ABL-Bio; Arrivent; AstraZeneca; Bayer; BridgeBio; Bristol Myers Squibb; Daiichi Sanko; Eli Lilly; Genentech; Gilead; Iovance Biotherapeutics; Merck; Novartis; Prelude; Regeneron; Synthekine; TILT Biotherapeutics. ntellectual Property for Motif Neoepitopes for Cancer Immunotherapy
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008073-9999-26-321-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until July 14th 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This continuing education activity is active starting October 1st 2026, and will expire on July 14th 2027.
Estimated time to complete this activity: 15 Minutes